Search Results

You are looking at 111 - 120 of 553 items for :

  • "pathology" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Karisa C. Schreck, Andrew Guajardo, Doris D.M. Lin, Charles G. Eberhart, and Stuart A. Grossman

presented with focal seizures and a left temporal lobe mass in 1998, which was observed until 2002 when he underwent surgery, and pathology results showed PXA. He underwent a second surgery in 2004 after demonstrating progression, with pathology still

Full access

Nikolaos A. Trikalinos, Amy Zhou, Maria B. Majella Doyle, Kathryn J. Fowler, Ashley Morton, Neeta Vachharajani, Manik Amin, Jesse W. Keller, William C. Chapman, Elizabeth M. Brunt, and Benjamin R. Tan

–approved Washington University Liver Cancer Registry. The registry has a retrospective and prospective component and collects information on consenting patients with various liver pathologies. We identified 123 patients with histopathologically proven cHCC-CCA in the

Full access

Benjamin O. Anderson, Kristine E. Calhoun, and Eric L. Rosen

mucin-secreting carcinoma . J Clin Pathol 1975 ; 28 : 711 – 716 . 22. Rosen P . Lobular carcinoma and hyperplasia . In: Rosen P, ed. Breast Pathology . Philadelphia : Lippincott-Raven ; 1997 : 507 – 544 . 23. Acs G Lawton

Full access

Venkata Pokuri, Norbert Sule, Yousef Soofi, Bo Xu, Khurshid Guru, and Saby George

transurethral resection (TUR) of the bladder tumor. After resection, the tumor base was cauterized and a mitomycin cocktail was left indwelling. Hematuria subsided with TUR. Based on pathology report, patient was started on neoadjuvant chemotherapy with a GC

Full access

Presenter: Jennifer J.D. Morrissette

generated and how to use them will be the most important aspect in getting the most out of genomic testing in treating your patients,” Jennifer J.D. Morrissette, PhD, Associate Professor, Department of Clinical Pathology and Laboratory Medicine, and

Full access

Ashley E. Ross

E. Ross, MD, PhD, of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Ross, Assistant Professor of Urology, Oncology, and Pathology, reviewed the evidence supporting the validity of currently available molecular prognostic tests

Full access

Lindsey M. Charo, Adam M. Burgoyne, Paul T. Fanta, Hitendra Patel, Juliann Chmielecki, Jason K. Sicklick, and Michael T. McHale

. Risk of recurrence is determined by tumor size, location, mitotic rate, and tumor rupture. Prediction tools, such as the modified NIH method, 8 the Armed Forces Institute of Pathology (AFIP; Miettinen criteria), 9 and the Memorial Sloan Kettering

Full access

Agata A. Bielska, Walid K. Chatila, Henry Walch, Nikolaus Schultz, Zsofia K. Stadler, Jinru Shia, Diane Reidy-Lagunes, and Rona Yaeger

colon masses. At total colectomy, the most advanced lesion was stage IIB. Pathology was notable for tumor-infiltrating lymphocytes (TILs) and the absence of MLH1 and PMS2 staining on immunohistochemistry ( Figure 1A ). Germline genetic testing revealed a

Full access

Vivek Subbiah and Kanishka Sircar

using a commercially available assay for mutational assessment of 5 diagnostic microsatellite sequences; a pathology specimen is noted as MSI-H if at least 2 of 5 microsatellites harbor mutations. NGS or immunohistochemistry for MMR proteins may be also

Full access

Katherine Cotangco, Mary Meram, and M. Patrick Lowe

subsequently underwent a dilation and curettage. Pathology results suggested leiomyosarcoma. A CT scan of the chest, abdomen, and pelvis revealed a right uterine body peripherally enhancing partially calcified necrotic 5.8 × 5.0-cm mass, bilateral pulmonary